Hoping to ease shortage, FDA fast-tracks generic form of cancer drug

February 4, 2013
Hoping to ease shortage, FDA fast-tracks generic form of cancer drug
Agency says new availability of doxorubicin will help people battling malignancy.

(HealthDay)—Seeking to ease potentially dangerous shortages of a key cancer drug, the U.S. Food and Drug Administration on Monday announced it had fast-tracked the approval of the first generic form of one such medication, Doxil (doxorubicin).

"The agency is committed to doing everything we can to address so that patients can get the medicines they need when they need them," Capt. Valerie Jensen, director of the Drug Shortage Staff at the FDA's Center for and Research, said in an agency news release. "For the past year, the FDA has been working to ensure that supplies of [] were not interrupted."

The new is made by Sun Pharma Global and will be available in 20 milligram and 50 milligram vials. Like brand-name Doxil, the injected drug is administered intravenously by a health care professional.

approved by the FDA have the same quality and strength as brand name drugs, and the generic manufacturing and packaging sites must pass the same quality standards as those of brand name drugs, the agency noted.

In response to the Doxil shortage, the FDA announced in February 2012 that it would allow temporary controlled importation of Lipodox, an alternative to Doxil that is produced by Sun Pharma Global but not approved in the United States.

The FDA also decided to allow the release of one lot of Janssen's Doxil made under an unapproved manufacturing process.

For the time being, the FDA said it will continue to allow the controlled importation of Lipodox. Once there is enough of Sun's generic version to meet projected demand, the FDA will halt imports of any unapproved doxorubicin product.

Shortages of potentially life-saving cancer medications have plagued the U.S. for the past two years.

Speaking at the annual meeting of the American Society for Clinical Oncology last June, Dr. Richard Schilsky, chair of ASCO's government relations committee, told reporters that some shortages had eased, "but there is still an unpredictable availability of many drugs and we are never sure exactly when a generic drug is suddenly going to go out of supply."

According to Schilsky, "that creates a tremendous amount of uncertainty—anxiety for our patients and great difficulty in planning if you're a physician."

In October of 2011, President Barack Obama signed a special Executive Order demanding action on the issue, which is often caused by interruptions in manufacturing as companies address safety issues.

Besides Doxil, other drugs that have seen interruptions in supply include nitrogen mustard (used to fight blood cancers), paclitaxel (important for breast cancer and other tumors), 5-FU (used in a variety of cancers), and methotrexate (important to treat certain lymphomas).

Explore further: FDA: New suppliers to ease 2 cancer drug shortages

More information: The U.S. Food and Drug Administration has more about drug shortages.

Related Stories

FDA: New suppliers to ease 2 cancer drug shortages

February 21, 2012
Federal regulators said Tuesday that they've approved new suppliers for two crucial cancer drugs, easing critical shortages - at least for the time being - that have patients worried about missing life-saving treatments.

New US legislation aims to curb cancer drug shortages (Update)

June 4, 2012
A critical shortage of generic drugs in the United States, particularly in cancer care, could be curbed with legislation now being hammered out by the US House and Senate, doctors said on Monday.

First generic versions of singulair approved

August 4, 2012
(HealthDay) -- The first generic versions of Singulair (montelukast sodium) have been approved by the U.S. Food and Drug Administration.

US House sends drug bill to Senate for final vote

June 20, 2012
(AP) — The House on Wednesday passed a major bill affecting the Food and Drug Administration that will increase inspections of drug manufacturing facilities overseas, while also funding review of new drugs at home.

First generic lexapro approved

March 14, 2012
(HealthDay) -- The Israeli drug maker Teva Pharmaceuticals has gained the first U.S. approval to market generic Lexapro (escitalopram) to treat depression and general anxiety disorder, the U.S. Food and Drug Administration ...

Generic boniva approved for osteoporosis

March 19, 2012
(HealthDay) -- The first generic versions of the once-monthly osteoporosis drug Boniva (ibandronate) have been approved by the U.S. Food and Drug Administration.

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.